SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (5424)9/28/1998 2:25:00 PM
From: Steve Fancy  Read Replies (6) of 6136
 
AGPH is receiving a lot of coverage of their rhinoviurus drug. This seems to be boosting sentiment nicely. May be over 30 for good. Michael Waldholz, a medical reporter for WSJ, just did a very bullish interview on AGPH's behalf on CNBC.

Now, can we keep the party going with some solid Remune news. Rick, do you have any new opinions on the Remune potential? AGPH seems to have laid a lot on the line with this drug.

sf
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News